Nature Communications (May 2022)
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer
- M. G. Filippone,
- D. Gaglio,
- R. Bonfanti,
- F. A. Tucci,
- E. Ceccacci,
- R. Pennisi,
- M. Bonanomi,
- G. Jodice,
- M. Tillhon,
- F. Montani,
- G. Bertalot,
- S. Freddi,
- M. Vecchi,
- A. Taglialatela,
- M. Romanenghi,
- F. Romeo,
- N. Bianco,
- E. Munzone,
- F. Sanguedolce,
- G. Vago,
- G. Viale,
- P. P. Di Fiore,
- S. Minucci,
- L. Alberghina,
- M. Colleoni,
- P. Veronesi,
- D. Tosoni,
- S. Pece
Affiliations
- M. G. Filippone
- European Institute of Oncology IRCCS
- D. Gaglio
- Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR) Segrate
- R. Bonfanti
- European Institute of Oncology IRCCS
- F. A. Tucci
- School of Pathology, University of Milan
- E. Ceccacci
- European Institute of Oncology IRCCS
- R. Pennisi
- European Institute of Oncology IRCCS
- M. Bonanomi
- ISBE.IT/Centre of Systems Biology
- G. Jodice
- European Institute of Oncology IRCCS
- M. Tillhon
- European Institute of Oncology IRCCS
- F. Montani
- European Institute of Oncology IRCCS
- G. Bertalot
- European Institute of Oncology IRCCS
- S. Freddi
- European Institute of Oncology IRCCS
- M. Vecchi
- European Institute of Oncology IRCCS
- A. Taglialatela
- Department of Genetics and Development, Columbia University Irving Medical Center
- M. Romanenghi
- European Institute of Oncology IRCCS
- F. Romeo
- European Institute of Oncology IRCCS
- N. Bianco
- European Institute of Oncology IRCCS
- E. Munzone
- European Institute of Oncology IRCCS
- F. Sanguedolce
- Department of Pathology, University of Foggia
- G. Vago
- School of Pathology, University of Milan
- G. Viale
- European Institute of Oncology IRCCS
- P. P. Di Fiore
- European Institute of Oncology IRCCS
- S. Minucci
- European Institute of Oncology IRCCS
- L. Alberghina
- ISBE.IT/Centre of Systems Biology
- M. Colleoni
- European Institute of Oncology IRCCS
- P. Veronesi
- European Institute of Oncology IRCCS
- D. Tosoni
- European Institute of Oncology IRCCS
- S. Pece
- European Institute of Oncology IRCCS
- DOI
- https://doi.org/10.1038/s41467-022-30375-8
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 19
Abstract
Finding biomarkers for targeted therapy is a promising approach to treat cancer. Here, the authors show that in breast cancer preclinical models and patients, CDK12 promotes tumourigenesis but induces selective vulnerability to therapies that target folate one-carbon metabolism.
